Heron Therapeutics, Inc.

NASDAQ:HRTX

Biotechnology

Healthcare
$0.27 +3.74%

+$0.01 today

Market cap
$51.94M
Beta
1.57
P/E (TTM)
-2.5
EPS (TTM)
-$0.16
52W Low $0.38High $2.30

Volume 1.81M

Average 2.90M

HRTX Inventory

Raw materials, work in progress, and finished goods held for sale.

Heron Therapeutics, Inc.NASDAQ: HRTX

Inventory · Q1 FY2026 · quarter ended Mar 2026

Inventory rises 62.5% from a year ago

Inventory stood at $92.54M at the end of Q1 FY2026, up 62.5% from a year earlier and down 0.2% from the prior quarter. Over 3 fiscal years it compounded at +19.3% a year.

Context

  • Inventory amounted to 37.6% of total assets at the end of Q1 FY2026, up 13.4 pp from a year earlier.
  • Inventory increased in 2 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether inventory keeps rising in the next quarterly balance sheet after a +62.5% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$92.54M-0.2% QoQ
Last fiscal yearDec 2025
$92.75M+74.5% YoY
Year agoMar 2025
$56.93M+62.5% since
Inventory past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+62.5%——
1 year+74.5%——
3-year CAGR+19.3%——
5-year CAGR——
10-year CAGR——

Inventory history

USD · from the balance sheet

Latest · FY2025
92.75M USD
Year-over-year change
+74.5%
4-year CAGR
+17.7%

Inventory vs competitors

How HRTX compares with its peers on the latest reported figures

  • HRTX's Mar 2026 inventory of $92.54M is the highest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +62.5% is the 2nd highest of 5, against a peer median of +46.7%.
  • Inventory amounts to 37.6% of total assets for HRTX, versus a peer median of 0.0%.
HRTX Competitors Peer median
Inventory for HRTX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
HRTXHeron Therapeutics, Inc.Mar 2026$92.54M +62.5%+19.3%37.6%
PLXProtalix BioTherapeutics, Inc.Mar 2026$30.47M +56.2%+15.3%29.8%
IVVDInvivyd, Inc.Mar 2026$25.45M +5658.4%—10.5%
CHRSCoherus Oncology, Inc.Mar 2026$4.83M +37.2%-56.6%1.8%
MDWDMediWound Ltd.Mar 2026$4.77M +33.3%+27.8%6.0%
SLSSELLAS Life Sciences Group, Inc.Sep 2026$0 ——0.0%
OABIOmniAb, Inc.Mar 2026$0 ——0.0%
EPRXEupraxia Pharmaceuticals Inc.Mar 2026$0 ——0.0%
TARAProtara Therapeutics, Inc.Mar 2026$0 ——0.0%
NTHINeonc Technologies Holdings, Inc.Mar 2026$0 ——0.0%
Peer median (excluding HRTX) $0+46.7%+15.3%0.0%

Competitors are the stored peer set for HRTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents90.54M15.36M28.68M25.8M28.65M
Short-term Investments67.04M69.49M51.73M33.48M17.98M
Net Receivables35.5M52.05M60.14M78.88M89.59M
Inventory48.38M54.57M42.11M53.16M92.75M
Other Current Assets013.96M6.12M17.69M9.1M
Total Current Assets254.42M205.44M188.77M209.01M238.07M
Property, Plant & Equipment (Net)33.56M29.81M25.6M17.65M12.4M
Goodwill00000
Intangible Assets00000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets17.72M15.71M8.13M6.48M5.41M
Total Non-current Assets51.28M45.52M33.73M24.13M17.81M
Total Assets305.71M250.95M222.51M233.15M255.88M
Account Payables3.87M3.59M3.8M11.71M8.99M
Short-term Debt00000
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities13.48M11.28M7.85M7.96M8.61M
Total Current Liabilities71.06M82.36M79.69M91.46M96.1M
Long-term Debt149.08M149.28M173.75M174.73M140.64M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities0241K241K615K4.81M
Total Non-current Liabilities157.08M155.02M176.79M175.34M145.45M
Total Liabilities228.14M237.38M256.48M266.8M241.54M
Common Stock1.02M1.19M1.5M1.52M1.88M
Retained Earnings(1.61B)(1.8B)(1.91B)(1.92B)(1.94B)
Accumulated OCI(6K)(19K)13K13K4K
Other Stockholders Equity00000
Minority Interest00000
Total Equity77.57M13.57M(33.97M)(33.65M)14.33M
Total Debt159.5M157.48M179.63M177.76M140.64M
Net Debt68.95M142.11M150.95M151.96M111.99M

Heron Therapeutics, Inc.

NASDAQ:HRTX

Intrinsic Alpha fair value

Locked

Current Price

$0.27

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.